Protocol NKI-AVL: blood sampling of healthy volunteers for immunological research

Protocol NKI-AVL: blood sampling of healthy volunteers for immunological research - Blood sampling of healthy volunteers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45890

Enrollment

Registered

2019-01-24

Start date

2019-04-05

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunobiology

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age above 35 years - Written informed consent

Exclusion criteria

Exclusion criteria: - History of cancer - Uuse of systemic immunosuppressive medication (eg. corticosteroids). Local use of corticosteroids (eg. topical or inhalation) is allowed. - Fever 14 days before blood withdrawal - Donated blood for the same program within the last 2 years - Pregnancy

Design outcomes

Primary

Measure	Time frame
Primary objective: mapping immune effector and suppressor functions in healthy individuals, to be used as a tool in immuno-oncology research	—

Secondary

Measure	Time frame
Secondary objectives: - Assessing and comparing the functionality of viral-epitope specific CD8+ T cells in healthy volunteers with the functionality of viral-epitope specific CD8+ T cells in cancer patients to gain insights into the possibility of a systemically exhausted CD8+ T cell state in these patients - Immunophenotyping of both myeloid and lymphoid cells in healthy controls to gain insights in immunological defects and immune evasion in cancer patients	—

Measure

Time frame

Secondary objectives: - Assessing and comparing the functionality of viral-epitope specific CD8+ T cells in healthy volunteers with the functionality of viral-epitope specific CD8+ T cells in cancer patients to gain insights into the possibility of a systemically *exhausted* CD8+ T cell state in these patients - Immunophenotyping of both myeloid and lymphoid cells in healthy controls to gain insights in immunological defects and immune evasion in cancer patients

—

Countries

Netherlands

Outcome results